Albert Bourla, Pfizer CEO (Efren Landaos/Sipa USA/Sipa via AP Images)
Pfizer no longer going to conduct interim analysis for Duchenne gene therapy study by end of year
Pfizer no longer plans to read out an interim analysis on its Duchenne muscular dystrophy gene therapy program by the end of the year, it …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
